Objectives: This study aimed to evaluate the therapeutic effcacy of custom-made mandibular advancement devices (MAD) in the control of primary snoring and sleep apnea and to correlate with anatomical changes identified through imaging tests.
Methods: Patients (n = 17) diagnosed with sleep apnea or primary snoring were included in this study and subsequently treated with MADs. Changes were assessed using a polysomnographic study (PSG), the Epworth Sleepiness Scale (ESS), and an imaging study with computed tomography scanning (CT).
Introduction: Insomnia is the most common of sleep disorders, it induces a wide variety of organic symptoms, including somatic and cognitive impairments. There are pharmacological drugs nowadays that help diminish sleep impairments due to insomnia. However, most of them seem to be worsening cognitive impairments, benzodiazepine receptor agonists, in particular, seem to induce an even worst deterioration of cognitive function.
View Article and Find Full Text PDFThe coronavirus disease (COVID-19) that broke out in China in December 2019 rapidly became a worldwide pandemic. In Mexico, the conditions requiring the declaration of a sanitary emergency were reached by the last week of March 2020, and health authorities' limited mobility and imposed social isolation were the main strategies to keep the virus from spreading. Thus, daily living conditions changed drastically in a few days, generating a stressful situation characterized by an almost complete lack of mobility, social isolation, and forced full-time interactions with family members.
View Article and Find Full Text PDFPurpose: To determine the relationship between the Epworth Sleepiness Scale (ESS) and the Subjective Sleep Quality (SSQ) or polysomnographic (PSG) features in patients with sleep-disordered breathing (SDB).
Methods: This is a retrospective study that included 646 untreated patients with a PSG diagnosis of primary snoring (PS) or obstructive sleep apnea syndrome. Patients with SDB were grouped into four categories according to ESS scores: no diurnal sleepiness (DS) = 0-6; mild DS = 7-12; moderate DS = 13-18, and severe DS = ≥19.